- Home
- ANL
as 07-11-2025 3:30pm EST
Stocks
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
| Founded: | 2004 | Country: | Cayman Islands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 56.0M | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 7.4K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $4.10 | Next Earning Date: | 08-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Adlai Nortye Ltd. News
ANL Breaking Stock News: Dive into ANL Ticker-Specific Updates for Smart Investing
MT Newswires
24 days ago
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
GlobeNewswire
3 months ago
Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025
Simply Wall St.
5 months ago
Adlai Nortye And 2 Other Penny Stocks On US Exchanges To Watch
Simply Wall St.
6 months ago
3 US Penny Stocks With Market Caps Over $80M To Watch
Simply Wall St.
10 months ago
Adlai Nortye Ltd. (NASDAQ:ANL) stock most popular amongst retail investors who own 42%, while employee share scheme hold 29%
GlobeNewswire
a year ago
Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress
GlobeNewswire
a year ago
Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors
The Telegraph
a year ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Compare ANL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANL Adlai Nortye Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.